亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients

医学 内科学 相对风险 置信区间 梅德林 临床试验 安慰剂 巨细胞病毒 荟萃分析 重症监护医学 器官移植 移植 免疫学 病毒性疾病 人类免疫缺陷病毒(HIV) 病理 疱疹病毒科 替代医学 法学 政治学
作者
Robin W.M. Vernooij,Mini Michael,Maleeka Ladhani,Angela C. Webster,Giovanni FM Strippoli,Jonathan C. Craig,Elisabeth M Hodson
出处
期刊:The Cochrane library [Elsevier BV]
卷期号:2024 (5) 被引量:2
标识
DOI:10.1002/14651858.cd003774.pub5
摘要

Background The risk of cytomegalovirus (CMV) infection in solid organ transplant recipients has resulted in the frequent use of prophylaxis to prevent the clinical syndrome associated with CMV infection. This is an update of a review first published in 2005 and updated in 2008 and 2013. Objectives To determine the benefits and harms of antiviral medications to prevent CMV disease and all‐cause death in solid organ transplant recipients. Search methods We contacted the information specialist and searched the Cochrane Kidney and Transplant Register of Studies up to 5 February 2024 using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Registry Platform (ICTRP) Search Portal, and ClinicalTrials.gov. Selection criteria We included randomised controlled trials (RCTs) and quasi‐RCTs comparing antiviral medications with placebo or no treatment, comparing different antiviral medications or different regimens of the same antiviral medications for CMV prophylaxis in recipients of any solid organ transplant. Studies examining pre‐emptive therapy for CMV infection are studied in a separate review and were excluded from this review. Data collection and analysis Two authors independently assessed study eligibility, risk of bias and extracted data. Summary estimates of effect were obtained using a random‐effects model, and results were expressed as risk ratios (RR) and their 95% confidence intervals (CI) for dichotomous outcomes and mean difference (MD) and 95% CI for continuous outcomes. Confidence in the evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Main results This 2024 update found four new studies, bringing the total number of included studies to 41 (5054 participants). The risk of bias was high or unclear across most studies, with a low risk of bias for sequence generation (12), allocation concealment (12), blinding (11) and selective outcome reporting (9) in fewer studies. There is high‐certainty evidence that prophylaxis with aciclovir, ganciclovir or valaciclovir compared with placebo or no treatment is more effective in preventing CMV disease (19 studies: RR 0.42, 95% CI 0.34 to 0.52), all‐cause death (17 studies: RR 0.63, 95% CI 0.43 to 0.92), and CMV infection (17 studies: RR 0.61, 95% CI 0.48 to 0.77). There is moderate‐certainty evidence that prophylaxis probably reduces death from CMV disease (7 studies: RR 0.26, 95% CI 0.08 to 0.78). Prophylaxis reduces the risk of herpes simplex and herpes zoster disease, bacterial and protozoal infections but probably makes little to no difference to fungal infection, acute rejection or graft loss. No apparent differences in adverse events with aciclovir, ganciclovir or valaciclovir compared with placebo or no treatment were found. There is high certainty evidence that ganciclovir, when compared with aciclovir, is more effective in preventing CMV disease (7 studies: RR 0.37, 95% CI 0.23 to 0.60). There may be little to no difference in any outcome between valganciclovir and IV ganciclovir compared with oral ganciclovir (low certainty evidence). The efficacy and adverse effects of valganciclovir or ganciclovir were probably no different to valaciclovir in three studies (moderate certainty evidence). There is moderate certainty evidence that extended duration prophylaxis probably reduces the risk of CMV disease compared with three months of therapy (2 studies: RR 0.20, 95% CI 0.12 to 0.35), with probably little to no difference in rates of adverse events. Low certainty evidence suggests that 450 mg/day valganciclovir compared with 900 mg/day valganciclovir results in little to no difference in all‐cause death, CMV infection, acute rejection, and graft loss (no information on adverse events). Maribavir may increase CMV infection compared with ganciclovir (1 study: RR 1.34, 95% CI: 1.10 to 1.65; moderate certainty evidence); however, little to no difference between the two treatments were found for CMV disease, all‐cause death, acute rejection, and adverse events at six months (low certainty evidence). Authors' conclusions Prophylaxis with antiviral medications reduces CMV disease and CMV‐associated death, compared with placebo or no treatment, in solid organ transplant recipients. These data support the continued routine use of antiviral prophylaxis in CMV‐positive recipients and CMV‐negative recipients of CMV‐positive organ transplants.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
和谐寻云完成签到,获得积分10
4秒前
18秒前
无极微光的应助被生气来找我采纳,获得20
20秒前
车访枫完成签到,获得积分10
25秒前
阔达的沛岚完成签到,获得积分10
29秒前
称心的忆山完成签到,获得积分10
33秒前
37秒前
44秒前
儒雅的白筠完成签到,获得积分10
1分钟前
1分钟前
1分钟前
yang1316发布了新的文献求助10
1分钟前
科研通AI6.2的应助被anya采纳,获得100
1分钟前
madeleinli的应助被科研通管家采纳,获得20
1分钟前
SciGPT的应助被yang1316采纳,获得30
1分钟前
秀丽的紫山完成签到,获得积分10
1分钟前
吉吉急急急完成签到 ,获得积分10
1分钟前
1分钟前
研友_VZG7GZ的应助被zoomer采纳,获得10
1分钟前
大气的夜雪完成签到,获得积分10
1分钟前
1分钟前
阳光幻巧完成签到,获得积分10
1分钟前
闪闪灵雁发布了新的文献求助10
1分钟前
2分钟前
2分钟前
悦耳的半兰完成签到,获得积分10
2分钟前
2分钟前
2分钟前
2分钟前
zoomer发布了新的文献求助10
2分钟前
2分钟前
2分钟前
anya发布了新的文献求助100
2分钟前
2分钟前
zoomer完成签到,获得积分10
2分钟前
所所的应助被SUNny采纳,获得10
2分钟前
2分钟前
丰富的雅绿完成签到,获得积分10
3分钟前
犹豫友卉完成签到,获得积分10
3分钟前
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179889
求助须知:如何正确求助?哪些是违规求助? 9570071
关于积分的说明 21808307
捐赠科研通 7775662
什么是DOI,文献DOI怎么找? 3433193
关于科研通互助平台的介绍 2557328
邀请新用户注册赠送积分活动 2478864